Investors seeking direct engagement with life sciences management teams will have a concentrated opportunity on September 17, 2026, when the Life Sciences Virtual Investor Forum convenes online. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the event features 30-minute live presentations followed by audience Q&A, with replays available on demand. The forum matters because it compresses a wide range of high-risk, high-reward therapeutic and diagnostic programs into a single day, allowing investors to question executives in real time rather than rely solely on filings.
The presenting lineup reflects several of the most closely watched areas in biotechnology. Sona Nanotech Inc. will discuss a photothermal cancer therapy built on gold nanorods, while Raphael Pharmaceutical brings cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease. Adaptin Bio, Inc. is set to present precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier. Acurx Pharmaceuticals, Inc. will highlight a new class of antibiotics in development for infections caused by bacteria listed as priority pathogens, and CytoDyn Inc. will cover a humanized monoclonal antibody being studied in solid-tumor oncology. Amplia Therapeutics Ltd. will present a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, and 4DMedical Ltd. will showcase FDA-cleared four-dimensional respiratory imaging.
David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized the value of live Q&A. “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company,” Shapiro said. “My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” That format is central to why the forum matters: it gives investors a chance to probe strategy, timelines, and risk factors that may not be fully addressed in written disclosures.
The event also underscores the reach of B2i Digital’s marketing platform. According to the company, its media network spans more than 800 news, broadcast, and trade outlets with a combined monthly audience exceeding 330 million, plus 1.7 million followers, 70,000 opt-in email subscribers, and a database of more than 235,000 capital markets contacts. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features public companies from exchanges including the NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets.
For investors, the forum’s implications extend beyond a single day of presentations. The mix of oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging offers a cross-section of sectors where clinical and regulatory milestones can rapidly change valuations. Live access to management, combined with on-demand replays, may help investors evaluate whether these companies can execute on their stated goals. Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum, and registration is open at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. Additional information on B2i Digital’s featured companies and conferences can be found at https://b2idigital.com.
